ESMO Congress 2022

ESMO

ESMO Congress 2022 Paris Expo Porte de Versailles

ESMO Congress 2022 Paris Expo Porte de Versailles

Oxford BioDynamics is proud to be attending the ESMO Congress 2022. Come see us at booth #419 to speak with our experts directly.

  1. Contact us to meet and learn about an innovation that will help transform how immunotherapy is recommended and administered.

Which patients will respond to checkpoint inhibitors?

Patients being considered for or currently receiving checkpoint inhibitor therapies. This is the only test that can predict an individual’s likelihood of response to checkpoint inhibitors and provides useful information at the cross-roads of a patient's treatment journey.

Current

Non-predictive diagnostic testing1
(PD-L1 IHC)

EpiSwitch® CiRT

ICI response prediction before treatment2
(PD-L1 IHC)

1: Hunter, E. et al. (2021), Development and validation of blood-based predictive biomarkers for response to PD-(L)-1 checkpoint inhibitors: evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications. MedRxiv (2021) doi:10.1101/2021.12.21.21268094;

2: Hunter, E. et al. (2019), SITC, J. Immunotherapy Cancer 7(282) P142 & P143

Register for a meeting. One of our ESMO attendees will contact you to arrange a meeting in Paris.

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

To learn more about how we use your information, read our Privacy Policy.